Evidence map›Paper›PMID 39741660›Full record

ArticleFrontiers in cardiovascular medicine2024

Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer.

Jonathan N Le, Jordan O Gasho, Olivia Peony, Asneh Singh, Katrina D Silos, Sungjin Kim, Anthony T Nguyen, Mitchell Kamrava, Amin Mirhadi, Behrooz Hakimian and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jonathan N LeDepartment of Medicine, Cedar-Sinai Medical Center, Los Angeles, CA, United States.
Jordan O GashoDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Olivia PeonyDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Asneh SinghDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Katrina D SilosDepartment of Medicine, Cedar-Sinai Medical Center, Los Angeles, CA, United States.
Sungjin KimBiostatistics Research Center, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Anthony T NguyenDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Mitchell KamravaDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Amin MirhadiDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Behrooz HakimianDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Karen L ReckampDepartment of Medicine, Cedar-Sinai Medical Center, Los Angeles, CA, United States.
Kamya SankarDepartment of Medicine, Cedar-Sinai Medical Center, Los Angeles, CA, United States.
Raymond H MakDepartment of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, United States.
Andriana P Nikolova *Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Katelyn M Atkins *Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors remains incompletely understood. Retrospective analysis of NSCLC patients with ≥1 echocardiogram post-osimertinib between 2007 and 2022 was performed. The cumulative incidence of grade ≥2 cardiac common terminology criteria for adverse events (CTCAE) was estimated and Fine and Gray regressions performed (non-cardiac death as competing risk). Eighty-five patients [mean [interquartile range, IQR], 68 [60-75] years; 67% female; 12% with pre-existing heart conditions] met inclusion criteria. With a median follow up of 34.7 months, the 2-year cumulative incidence of grade ≥2 and grade ≥3 cardiac events were 19.2% and 8.5%, respectively. There was an increased risk of grade ≥2 cardiac CTCAE with pre-existing arrhythmia [hazard ratio(HR) 3.90, 95%CI, 1.11-13.72;

Indexed as

cardiac toxicityechocardiogramEGFRlung cancerosimertinib

Identifiers

PMID39741660
PMCPMC11685755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.